Investigational drug · Phase 3
Levilimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rheumatoid Arthritis.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "Levilimab"
First trial start
2022
Dec 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Levilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Levilimab" as an intervention, largest first.
- A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid ArthritisPivotal-lookingActive, not recruiting
BiocadIndustry
NCT05800327 · 261 participants (planned) · Start Dec 7, 2022 · Primary completion Sep 2024
Drug: Levilimab · For: Rheumatoid Arthritis
Sites: Saint Petersburg, Russia
- A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19Pivotal-lookingCompleted
BiocadIndustry
NCT04397562 · 206 participants · Start Apr 29, 2020 · Primary completion Jul 3, 2020
Drug: Levilimab; Placebo · For: COVID-19
Sites: Kaluga, Russia; Makhachkala, Russia; Moscow, Russia · 16 sites in all
- Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid ArthritisPivotal-lookingCompleted
BiocadIndustry
NCT04227366 · 154 participants · Start Nov 19, 2019 · Primary completion Mar 15, 2021
Drug: BCD-089; Placebo and 1 more · For: Rheumatoid Arthritis
Sites: Moscow, Russia
- The BCD-089 (aIL6R) in Patients With Active Rheumatoid ArthritisPivotal-lookingCompleted
BiocadIndustry
NCT03455842 · 105 participants · Start Feb 1, 2018 · Primary completion Dec 31, 2018
Drug: BCD-089, 162 mg, s/c, qw; BCD-089, 162 mg, s/c, q2w and 1 more · For: Seropositive RA
Sites: Minsk, Belarus; Chelyabinsk, Russia; Kazan', Russia · 4 sites in all
BiocadIndustry
NCT03103438 · 19 participants · Start Nov 2016 · Primary completion May 2017
Drug: BCD-089 · For: Healthy
Sites: Saint Petersburg, Russia
Newest research
PubMed records naming it or its code names, newest first.
- [Evaluation of the efficacy and safety of levilimab in the treatment of patients with rheumatoid arthritis in real practice].
Myasoutova ER, Iuskaeva AR, Kostakova LS, et al. · Ter Arkh 2025
- Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR.
Mazurov VI, Nasonov EL, Lila AM, et al. · Dokl Biochem Biophys 2024
- [Efficacy and safety of levilimab in the treatment of patients with rheumatoid arthritis].
Bolotova EV, Yakovleva EV, Ilinykh EK, et al. · Ter Arkh 2024
- Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L, Assi R, Evrenoglou T, et al. · Cochrane Database Syst Rev 2023
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A, Sepriano A, Bergstra SA, et al. · Ann Rheum Dis 2023
- [Clinical cases of complicated diverticulitis against the background of severe course COVID-19. Case report].
Pshenichcnaya NY, Ponezheva ZB, Marzhokhova AR, et al. · Ter Arkh 2022
Also in development for Rheumatoid Arthritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.